Q1 EPS Estimates for USANA Health Sciences Cut by Sidoti Csr

USANA Health Sciences, Inc. (NYSE:USNA) – Equities researchers at Sidoti Csr dropped their Q1 2025 earnings per share estimates for shares of USANA Health Sciences in a research report issued to clients and investors on Tuesday, February 18th. Sidoti Csr analyst A. Lebiedzinski now anticipates that the company will post earnings per share of $0.77 for the quarter, down from their previous estimate of $0.84. The consensus estimate for USANA Health Sciences’ current full-year earnings is $2.45 per share. Sidoti Csr also issued estimates for USANA Health Sciences’ Q2 2025 earnings at $0.68 EPS, Q3 2025 earnings at $0.70 EPS, Q4 2025 earnings at $0.74 EPS, FY2025 earnings at $2.89 EPS, Q1 2026 earnings at $0.89 EPS, Q2 2026 earnings at $0.86 EPS, Q3 2026 earnings at $0.90 EPS and FY2026 earnings at $3.59 EPS.

Other research analysts have also issued reports about the company. DA Davidson raised their price target on USANA Health Sciences from $35.00 to $38.00 and gave the stock a “neutral” rating in a research report on Thursday, January 2nd. Sidoti lowered USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday. Finally, StockNews.com lowered USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday, February 14th.

USANA Health Sciences Stock Down 0.8 %

NYSE:USNA opened at $31.85 on Thursday. USANA Health Sciences has a 12-month low of $30.13 and a 12-month high of $50.32. The firm has a market capitalization of $607.02 million, a P/E ratio of 11.25, a P/E/G ratio of 0.90 and a beta of 0.87. The stock’s fifty day simple moving average is $33.81 and its 200-day simple moving average is $36.77.

Institutional Trading of USANA Health Sciences

Hedge funds and other institutional investors have recently modified their holdings of the company. R Squared Ltd acquired a new stake in shares of USANA Health Sciences in the 4th quarter valued at about $28,000. Safe Harbor Fiduciary LLC acquired a new stake in shares of USANA Health Sciences in the third quarter valued at about $30,000. KBC Group NV increased its position in shares of USANA Health Sciences by 96.6% in the third quarter. KBC Group NV now owns 1,056 shares of the company’s stock valued at $40,000 after acquiring an additional 519 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of USANA Health Sciences in the fourth quarter valued at about $83,000. Finally, Quantbot Technologies LP acquired a new stake in shares of USANA Health Sciences in the fourth quarter valued at about $132,000. Institutional investors and hedge funds own 54.25% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.